StockDocs
Main Newswire Learn
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
SVRA

Savara Inc.

SVRA Nasdaq Pharmaceutical Preparations EDGAR ↗
$4.26
-0.95 -18.23%

Key statistics

from XBRL data in SEC filings
Market cap ⓘ
$940M
Revenue (TTM) ⓘ
$257K
Net income (TTM) ⓘ
-$153M
EPS (TTM) ⓘ
$-0.61
P/E ratio ⓘ
—
Dividend yield ⓘ
—
Free cash flow ⓘ
-$101M
Cash ⓘ
$29.8M
Total assets ⓘ
$156M
Gross margin ⓘ
190.3%
52-week range ⓘ
$4.00 – $7.01

AI briefing

from the latest 10-K, 10-Q and 8-K events

Savara Inc. is a clinical-stage biopharmaceutical company with a single investigational product, molgramostim inhalation solution (MOLBREEVI), in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

What they do

Savara has no approved products and no meaningful product revenue; its sole program is MOLBREEVI, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) biologic delivered via a proprietary PARI eFlow Nebulizer System. The company completed the Phase 3 IMPALA-2 trial in autoimmune PAP (164 patients enrolled against a target of 160) and submitted a BLA to the FDA in March 2025. After an FDA Refusal to File in May 2025, Savara resubmitted the BLA in December 2025, and in February 2026 the FDA filed the BLA and granted Priority Review.

Revenue drivers

  • MOLBREEVI (molgramostim inhalation solution) — The company's only product candidate, in Phase 3 for autoimmune PAP; if approved it would be the sole source of product revenue, but it is not yet approved and generates no revenue today.
  • Prior-period collaboration/other revenue — Historical annual revenue was minimal and intermittent ($54K in 2015, $400K in 2016, $0 in 2017 and 2019, $257K in 2020), indicating no ongoing commercial revenue base.
  • No approved products or marketed portfolio — The 10-K states the company has never obtained regulatory approval for or commercialized a product candidate, so there are currently no product-line revenue streams.

Recent performance

Savara has no product revenue in recent periods and continues to fund development at a loss. Annual net loss widened from $43.0M in 2021 to $118.8M in 2025, with diluted EPS moving from -$0.32 to -$0.53 over the same span. Operating cash use increased from $40.1M in 2021 to $101.0M in 2025. At June 30, 2026, total assets were $192.1M, total liabilities $48.5M, shareholder equity $143.7M, and cash and equivalents $41.8M, with $30.1M of long-term debt.

Strategy

Savara's stated goal is to become a leader in rare respiratory therapeutics through development and commercialization of MOLBREEVI in autoimmune PAP. It is pursuing regulatory approval, with the BLA filed by the FDA in February 2026 under Priority Review, and is working to validate commercial-scale manufacturing. It selected FUJIFILM Diosynth Biotechnologies to complete technology transfer from GEMA and to manufacture commercial drug substance, validated with three process performance qualification batches, while Patheon manufactures drug product. PARI supplies the proprietary eFlow nebulizer under a long-term agreement, and the company plans a second-source drug product manufacturer post-commercialization.

Risks

  • Single-product dependence — The company states it is substantially dependent on the clinical, regulatory, and commercial success of its sole product candidate, MOLBREEVI, and has never obtained approval for or commercialized any product.
  • Regulatory approval uncertainty — The BLA received a Refusal to File from the FDA in May 2025 and was only resubmitted in December 2025 and filed in February 2026, so approval may still be delayed, conditioned, or denied.
  • Manufacturing and supply chain risk — Commercial supply depends on a technology transfer to FUJIFILM for drug substance and Patheon for drug product, with a second-source drug product manufacturer not yet qualified.
  • Funding and going-concern risk — With no product revenue and operating cash use of $101.0M in 2025 against $41.8M of cash at June 30, 2026 and $30.1M of long-term debt, the company will require additional capital.

Outlook

Management's stated priority is advancing MOLBREEVI toward potential approval, supported by the FDA's February 2026 filing and Priority Review of the resubmitted BLA. The company is also working to complete commercial-scale manufacturing validation with FUJIFILM and to maintain a dual-source supply chain. No product revenue is expected ahead of a potential approval; the company has guided only through its disclosures of continued spending and capital needs.

Recent SEC filings

40 most recent
Annual, quarterly & current reports